High Complete Remission Rate in Hairy Cell Leukemia Treated with 2-Chlorodeoxyadenosine

References

• Bouroncle B. A., Wiseman G. B. K., Doan C. A. Leukemic Reticuloendotheliosis. Blood 1958; 13: 609–630
   PubMed Web of Science ®Google Scholar
• Catovsky D., Pettit J. E., Galton D. A. G., et al. Leukaemic Reticuloendotheliosis (“Hairy” cell leukaemia”): a distinct clinico-pathological entity. Br. J. Haematol. 1974; 26: 9–27
   PubMed Web of Science ®Google Scholar
• Yam L. T., Li C. Y., Lam K. W. Tartrate-re-sistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendotheliosis. N. Engl. J. Med. 1971; 284: 351–353
   Web of Science ®Google Scholar
• Jansen J., Hermans J. Splenectomy in hairy cell leukemia: a retrospective multicenter analysis. Cancer 1981; 47: 2066–2076
   PubMed Web of Science ®Google Scholar
• Golomb H. M., Vardiman J. W. Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 1983; 61: 349–352
   PubMed Web of Science ®Google Scholar
• Quesada J. R., Reuben J., Manning J. T., et al. Alpha interferon for induction of remission in hairy cell leukemia. N. Engl. J. Med. 1984; 310: 15–19
   PubMed Web of Science ®Google Scholar
• Jacobs A. D., Champlin R. E., Golde D. W. Recombinant α-2-Interferon for hairy cell leukemia. Blood 1984; 65: 1017–1020
   Web of Science ®Google Scholar
• Foon K. A., Maluish A. E., Abrams P. G., et al. Recombinant leukocyte A Interferon therapy for advanced hairy cell leukemia. Am. J. Med. 1986; 80: 351–356
   PubMed Web of Science ®Google Scholar
• Golomb H. M., Fefer A., Golde D. W., et al. Sequential evaluation of alpha 2b-Interferon treatment in 128 patients with hairy cell leukemia. Sem. Oncol. 1987; 14: 13–17
   PubMed Web of Science ®Google Scholar
• Lauria F., Foa R., Raspadori D., et al. Treatment of hairy cell leukemia with α-Interferon (α-lFN). Eur. J. Cancer 1988; 24: 195–200
   Web of Science ®Google Scholar
• Ratain M. J., Golomb H. M., Vardiman J. W., et al. Relapse after interferon alfa-2b therapy for hairy cell leukemia: analysis of prognostic variables. J. Clin. Oncol. 1987; 6: 1714–1721
   Web of Science ®Google Scholar
• Golomb H. M., Schmidt K., Vardiman J. W. Chlorambucil therapy of twenty-four post-splenectomy patients with progressive hairy cell leukemia. Sem. Oncol. 1984; 11: 502–505
   PubMed Web of Science ®Google Scholar
• Spiers A. S. D., Parekh S. J., Bishop M. B. Hairy cell leukemia: induction of complete remission with pentostatin (2′-deoxycoformycin). J. Clin. Oncol. 1984; 2: 1336–1342
   PubMed Web of Science ®Google Scholar
• Johnston J. B., Eisenhauer E., Corbett W., et al. Efficacy of 2′-deoxycoformycin in hairy cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group. J. Nail. Cancer Inst. 1988; 80: 765–769
   PubMed Web of Science ®Google Scholar
• Kraut E. H., Bouroncle B. A., Grever M. R. Pentostatin in the treatment of advanced hairy cell leukemia. J. Clin. Oncol. 1989; 7: 168–172
   PubMed Web of Science ®Google Scholar
• Dearden C., Catovsky D. Treatment of hairy cell leukaemia with 2′-deoxycoformycin. Leuk. Lymph. 1990; 1: 179–185
   PubMedGoogle Scholar
• Cassileth P. A., Cheuvart B., Spiers A. S. D., et al. Pentostatin induces durable remissions in hairy cell leukemia. J. Clin. Oncol. 1991; 9: 243–246
   PubMed Web of Science ®Google Scholar
• Piro L. D., Carrera C. J., Carson D. A., et al. Lasting remission in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N. Engl. J. Med. 1990; 322: 1117–1121
   PubMed Web of Science ®Google Scholar
• Saven A., Piro L. D. Treatment of hairy cell leukemia. Blood 1992; 79: 1111–1120
   PubMed Web of Science ®Google Scholar
• Estey E. H., Kurzrock R., Kantarjian H. M., et al. Treatment of hairy cell leukemia with 2-Chlorodeoxyadeno-sine (2-CdA). Blood 1992; 79: 882–887
   PubMed Web of Science ®Google Scholar
• Juliusson G., Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-Chloro-2′-Deoxyadenosine (CdA): relation to opportunistic infections. Blood 1992; 79: 888–894
   PubMed Web of Science ®Google Scholar
• Falini B., Pileri S., Flenghi L., et al. Selection of a panel of monoclonal antibodies for monitoring residual disease in peripheral blood and bone marrow of interferon-treated hairy cell leukaemia patients. Br. J. Haematol. 1990; 76: 460–468
   PubMed Web of Science ®Google Scholar
• Hounieu H., Chittal S. M., Al Saati T., et al. Hairy cell leukemia—diagnosis of bone marrow involvement in paraffin-embedded sections by monoclonal antibody DBA44. Am. Clin J. Pathol., in press
   Google Scholar
• Cordell J., Falini B., Erber W., et al. Immunoen-zymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J. Histochem. Cy-tochem. 1984; 32: 219–229
   PubMed Web of Science ®Google Scholar
• Ambrosetti A., Semenzato G., Prior M., et al. Serum levels of soluble interleukin-2 receptor in hairy cell leukaemia: a reliable marker of neoplastic bulk. Br. J. Haematol. 1989; 73: 181–186
   PubMed Web of Science ®Google Scholar
• Lauria F., Rondelli D., Raspadori D., et al. Serum soluble interleukin-2 receptor levels in hairy cell leukemia patients: correlation with clinical and haematological parameters and with α-interferon treatment. Leuk. Lymph. 1992; 7: 103–107
   PubMed Web of Science ®Google Scholar
• Chilosi M., Semenzato G., Cetto G., et al. Soluble interleukin-2 receptor in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant α-interferon therapy on clinical parameters and natural killer in vitro activity. Blood 1987; 70: 1530–1535
   PubMed Web of Science ®Google Scholar
• Steis R. G., Marcon L., Clark J., et al. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood 1988; 71: 1304–1309
   PubMed Web of Science ®Google Scholar
• Richards J. M., Mick R., Latta J. M., et al. Serum soluble interleukin-2 receptor is associated with clinical and pathological disease status in hairy cell leukemia. Blood 1990; 76: 1941–1945
   PubMed Web of Science ®Google Scholar
• Barak V., Gineburg M., Kalickman I., Polliack A. Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in lymphoma and chronic lymphocyte leukemia. Leuk. Lymph. 1992; 7: 431–438
   PubMed Web of Science ®Google Scholar
• Ho A. D., Großmann M., Knauf W., et al. Plasma levels of soluble CD8 antigen and Interleukin-2 receptor antigen in patients with hairy cell leukemia, relationship with splenectomy and with clinical response to therapy. Leukemia 1989; 3: 718–723
   PubMed Web of Science ®Google Scholar
• Beutler E., Piro L. D., Saven A., et al. 2-Chloro-deoxyadenosine (2-CdA): a potent chemotherapeutic and im-munosuppressive nucleoside. Leuk. Lymph. 1991; 5: 1–8
   PubMed Web of Science ®Google Scholar